Company diagnostic
Biodefense and specialty pharma
EBS
Emergent BioSolutions
Back to profit with $156.8M of free cash flow; the two sized gaps are inventory at 384.2 days against a 130-day median and adjusted operating margin of 15.1% against a 20% median.
Why now
In the news
Emergent BioSolutions announced on October 16, 2026 that chief financial officer Richard Lindahl will retire at the end of the year, with treasurer Frank Vargo becoming interim CFO on January 1, 2027.
Business health score
45
Out of 100
Addressable estimate
$36.9M addressable estimate (observed gap $58.7M)
Revenue
$742.9M (FY2025)
Operating margin
13.5%
As reported
Filing
Form 10-K, fiscal year 2025 (year ended December 31, 2025)
Run
November 1, 2026
Processing
5
minutes
Output
39
-page PDF and Excel model
Data quality
90
Point-in-time analysis from the filing and run date shown. The news context reflects reporting available on that date, and this page is not updated as events move on.
Score by dimension
Financial health
34
Growth potential
Strategic readiness
Market position
Innovation and digital
Operational efficiency
58
First 100-day action
Run an inventory audit across all facilities, classifying SKUs by expiry profile, government MCM contract hold requirements and slow-moving commercial stock.
How it compares
- Net margin: 7.1% vs peer median 16% (Behind median)
- EBITDA margin: 26.4% vs peer median 28% (Behind median)
- Return on assets: 4% vs peer median 8% (Behind median)
- Debt to equity: 1.13x vs peer median 0.9x (Behind median)
- SG&A, % of revenue: 25.1% vs peer median 27.0% (Better than median)
- Asset turnover: 0.56x (Better than median)
- Days sales outstanding: 41.4 days vs peer median 75 days (Top quartile)
- Gross margin: 56.1% vs peer median 72% (Behind median)
- Inventory turnover: 0.95x vs peer median 2.81x (Well behind median)
- Inventory days: 384.2 days vs peer median 130 days (Well behind median)
Top three levers
Lever 1
Inventory optimization and supply chain rationalization
Why this lever
Days inventory outstanding of 384.2 days trails the 130-day sector median by 254.2 days, with $343.4M held in inventory against annual cost of revenue of $326.2M. Closing the gap requires SKU-level demand forecasting aligned with government MCM contract minimum hold requirements, clearing slow-moving commercial inventory and renegotiating just-in-time raw material deliveries with API suppliers. Contract hold requirements may limit how much is addressable.
Size
$22.3M a year
Carrying benefit on a one-time $227.2M cash release
Lever 2
Operating margin expansion via cost structure optimization
Why this lever
On the adjusted basis, operating margin of 15.1% (13.5% reported, excluding $12.2M of exceptional items) trails the 20% sector median by 4.9 points, an observed gap of $36.4M, of which 40%, $14.6M, is treated as addressable. The report points to R&D portfolio prioritization, SG&A discipline and reallocation of resources from closed facilities; SG&A at 25.1% of revenue already beats the 27% median. The August 2026 restructuring, which cut approximately 93 jobs, closed two Gaithersburg wet labs and targeted $40M in annualized savings, bears on this gap; re-measure on the latest filing before treating the full amount as open.
Size
$14.6M
Observed gap $36.4M
Lever 3
Debt paydown and interest expense reduction
Why this lever
Total debt of $589.7M against equity of $522.6M gives debt to equity of 1.13x, above the 0.9x sector median. Interest expense of $59.3M consumes 59% of operating income, for interest coverage of 1.69x against a 6x median. The report points to free cash flow of $156.8M as capacity for paydown but does not size the lever. The company refinanced its term loan with a new $150M facility in Q2 2026, which bears on this initiative; confirm the current position first.
Size
Directional
Not sized in the report
Questions for management
- What is the current status of the August 2026 restructuring ($40M annualized savings target)? How much has been realized to date, and what is the timeline for full realization? How does this progress compare to the $14.6M operating margin improvement opportunity identified in the value creation roadmap?
- What is the detailed breakdown of the $343.4M inventory balance by product line (MCM vs. commercial), expiry profile, and government contract hold requirements? How much inventory can be safely reduced without violating government procurement agreements or creating stockout risk?
- What is the government's demand forecast for anthrax, smallpox, and botulism countermeasures over the next 3-5 years? How confident is management in the timing and magnitude of the MCM contract awards and options reported in FY2025?
Summary
Emergent BioSolutions returned to profit in fiscal 2025, with net income of $52.6M against a $190.6M loss in FY2024, operating income of $100.1M and free cash flow of $156.8M. Revenue fell 28.8% to $742.9M as Commercial Products, mainly naloxone, dropped 43.3% to $226.1M and MCM Products declined 10.4% to $456.7M. Debt to equity is 1.13x against a 0.9x median, and interest coverage is 1.69x.
The report sizes two observed gaps totaling $58.7M, with an addressable estimate of $36.9M; those addressable shares are estimates to be tested. Inventory of $343.4M sits at 384.2 days against a 130-day median. Closing that gap would release $227.2M of cash once, which is not recurring profit; only the $22.3M annual carrying benefit counts in the value bridge. On the adjusted basis, operating margin of 15.1% trails the 20% median by 4.9 points, an observed gap of $36.4M of which $14.6M is treated as addressable. Debt reduction, gross margin recovery and NARCAN channel stabilization are directional and not sized. Later developments, including the August 2026 restructuring, may already bear on three of the levers.
The first 100-day move is an inventory audit across all facilities, classifying SKUs by expiry profile, government contract hold requirements and slow-moving commercial stock, alongside work with government partners to validate MCM demand forecasts and buffer stock levels.
What this report does not cover
Only two of six scorecard dimensions could be rated against the peer set. Employee count and the split of SG&A into selling and administrative costs were not disclosed, and segment-level margins are not in the extracted data. Debt reduction, gross margin recovery and NARCAN channel stabilization are not sized, and neither are the segment-level MCM procurement and naloxone opportunities. Later developments, including the August 2026 restructuring, the Q2 2026 term loan refinancing and the reported Baltimore-Camden facility sale, come from market intelligence and are not reflected in the FY2025 figures.
More company diagnostics and category insights
All insightsRun this on a company you are assessing
Request a free analysisThis analysis is generated by the ValueChaser platform from the company's public Form 10-K, ValueChaser benchmarks and public market intelligence. It is not investment advice, does not reflect any non-public information and is not affiliated with or endorsed by the company.
